SMNR — Semnur Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.84bn
- $1.84bn
- 10
- 66
- 29
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -9.04% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Semnur Pharmaceuticals, Inc. is a clinical-late stage specialty pharmaceutical company focused on the development and commercialization of non-opioid pain therapies. The Company's lead program, SP-102, is non-opioid gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. It is developing SP-102 to address problems associated with corticosteroid products that are used in practice but not approved for epidural injection or the treatment of sciatica. SP-102 is a Phase III sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a pre-filled glass syringe for delivery via an epidural injection. SP-102 allows for use of potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is formulated without the use of preservatives and packaged in a pre-filled syringe.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- September 22nd, 2025
- Public Since
- April 7th, 2022
- No. of Shareholders
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 229,740,978
- Address
- 960 San Antonio Road, PALO ALTO, 94303
- Web
- Phone
- +1 6505164310
- Auditors
- Marcum LLP
Upcoming Events for SMNR
Similar to SMNR
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Semnur Pharmaceuticals share price?
As of Today at 22:09 UTC, shares in Semnur Pharmaceuticals are trading at $8.00. This share price information is delayed by 15 minutes.
How has the Semnur Pharmaceuticals share price performed this year?
Shares in Semnur Pharmaceuticals last closed at $8.00 and the price had moved by -33.33% over the past 365 days. In terms of relative price strength the Semnur Pharmaceuticals share price has underperformed the S&P500 Index by -43.68% over the past year.
What are the analyst and broker recommendations for Semnur Pharmaceuticals?
There is no consensus recommendation for this security.
Find out moreWhat is the Semnur Pharmaceuticals dividend yield?
Semnur Pharmaceuticals does not currently pay a dividend.
Does Semnur Pharmaceuticals pay a dividend?
Semnur Pharmaceuticals does not currently pay a dividend.
When does Semnur Pharmaceuticals next pay dividends?
Semnur Pharmaceuticals does not currently pay a dividend.
How do I buy Semnur Pharmaceuticals shares?
To buy shares in Semnur Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Semnur Pharmaceuticals?
As of the previous close price of $8.00, shares in Semnur Pharmaceuticals had a market capitalisation of $1.84bn.
Where are Semnur Pharmaceuticals shares listed?
Here are the trading details for Semnur Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SMNR
What kind of share is Semnur Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Semnur Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Semnur Pharmaceuticals share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Semnur Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Semnur Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -36.89%.
As of the last closing price of $8.00, shares in Semnur Pharmaceuticals were trading -17.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Semnur Pharmaceuticals PE Ratio?
The Semnur Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Semnur Pharmaceuticals?
We do not have data on Semnur Pharmaceuticals' directors